HR Positive/HER2 Low Expression Metastatic Breast Cancer
1 clinical trials · Condition
◉ Watch HR Positive/HER2 Low Expression Metastatic Breast Cancer
| Record | Firm | Date |
|---|---|---|
| Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial) (NCT05904964) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2023-07-01 |
Track HR Positive/HER2 Low Expression Metastatic Breast Cancer automatically
Every clearance here is in the API, with alerts when new ones post.